Systemic mastocytosis: 2023 update on diagnosis and management in adults.
Expert opinion on emerging drugs(2023)
摘要
Diagnosis and classification of SM has evolved over years. The most recent WHO and ICC classification improved SM diagnostic work-up, providing clinicians with a clear and simplified diagnostic scheme. New approved targeted therapies such as midostaurin and avapritinib modified the treatment paradigm in patients in advanced stage, and next-generation inhibitors actually investigated in clinical trials are expected in the next future.
更多查看译文
关键词
Systemic mastocytosis,ICC,tyrosine-kinase inhibitors,avapritinib,elenestinib,bezuclastinib
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要